Accueil   Diary - News   All news Focus on Fab'entech

Focus on Fab’entech

Fab'entech , innovative biopharmaceutical company member of Lyonbiopole is specialized since five years already , in the Treatment of Emerging Infectious Diseases. The company announces this month processing production of anti-Ebola traitement it launched a Developed in collaboration with the World Health Organization (WHO) and with the support of the European Medicines Agency (EMA).


A propos de Fab'entech

Fab’entech is a biopharmaceutical company specialising in treatments against emerging infectious diseases since 2009.
The rapid emergence of viral diseases such as avian influenza and haemorrhagic fever is creating new pandemic risks. Emergency therapies to help infected patients get through the critical stage and reduce the spread of infection are urgently needed.
To address these public health threats, Fab’entech has developed anti-infective passive immunotherapy solutions based on highly purified specific polyclonal antibodies. Once administered to patients, antibodies immediately neutralise circulating viruses and hinder development of the disease.
Fab’entech’s product development and production platform uses technology licensed from Sanofi Pasteur, capitalising on existing collaboration and sub-contracting agreements. This platform ensures a rapid response to epidemic situations using a well-established manufacturing process. To date, Fab’entech has already developed the first treatment against H5N1 influenza, Fabenflu®. Its R&D portfolio includes several key targets: H7N9 avian influenza, MERS-CoV, Hendra and Nipah viruses, Crimean-Congo and Lassa haemorrhagic fevers.